Preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with newly diagnosed primary operable cT₃NxM0 low rectal cancer: a phase II study.

Ofner D, Devries AF, Schaberl-Moser R, Greil R, Rabl H, Tschmelitsch J, Zitt M, Kapp KS, Fastner G, Keil F, Eisterer W, Jäger R, Offner F, Gnant M, Thaler J Strahlenther Onkol. 2011 Feb,187(2):100-7. doi: 10.1007/s00066-010-2182-6. Epub 2011 Jan 21.

Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.

Fiegl M, Falkner F, Steurer M, Zojer N, Hopfinger G, Haslbauer F, Winder G, Voskova D, Andel J, Lang A, Brychtova Y, Mayer J, Greil R, Gastl G Ann Hematol. 2011 Sep,90(9):1083-91. doi: 10.1007/s00277-011-1192-5. Epub 2011 Feb 25.

Lysine residue at position 22 of the AID protein regulates its class switch activity.

Geisberger R, Huemer M, Gassner FJ, Zaborsky N, Egle A, Greil R. PLoS One. 2012,7(2):e30667. doi: 10.1371/journal.pone.0030667. Epub 2012 Feb 20.

Zoledronic acid for adjuvant use in patients with breast cancer.

Ressler S, Mlineritsch B, Greil R. Expert Rev Anticancer Ther. 2011 Mar,11(3):333-49. doi: 10.1586/era.11.13.

Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14.

Tausch C, Steger GG, Haid A, Jakesz R, Fridrik MA, Reitsamer R, Pöstlberger S, Lang A, Gnant M, Greil R. Breast J. 2011 May-Jun,17(3):230-8. doi: 10.1111/j.1524-4741.2011.01073.x. Epub 2011 Mar 31.

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D, Marosi C, Ochsenbein A, Pichler J, Roelcke U, Weder P, Zander T, Wick W, Weller M. Acta Oncol. 2011 Jun,50(5):630-5. doi: 10.3109/0284186X.2011.572913. Epub 2011 Apr 18.

Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial.

Pfeiler G, Königsberg R, Fesl C, Mlineritsch B, Stoeger H, Singer CF, Pöstlberger S, Steger GG, Seifert M, Dubsky P, Taucher S, Samonigg H, Bjelic-Radisic V, Greil R, Marth C, Gnant M. J Clin Oncol. 2011 Jul 1,29(19):2653-9. doi: 10.1200/JCO.2010.33.2585. Epub 2011 May 9.

Combination therapy of lapatinib and Capecitabine for ErbB2-positive metastatic or locally advanced breast cancer: results from the Lapatinib Expanded Access Program (LEAP) in Central and Eastern Europe.

Greil R, BorГ…ВЎtnar S, PetrГЎkovГЎ K, Marcou Y, Pikiel J, Wojtukiewicz MZ, Koza I, Steger GG, Linn M, Das Gupta A, Cwiertka K. Onkologie. 2011,34(5):233-8. doi: 10.1159/000327710. Epub 2011 Apr 26.

Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.

Grundbichler M, Mlineritsch B, Ressler S, Moik M, Kappacher A, Rosenlechner S, Greil R. Oncology. 2011,80(1-2):34-41. doi: 10.1159/000328086. Epub 2011 May 23.

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial.

Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R Lancet Oncol. 2011 Jul,12(7):631-41. doi: 10.1016/S1470-2045(11)70122-X. Epub 2011 Jun 5.